[Remote] Director, Oncology Patient Support Operations at Corcept Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Oncology, BiotechnologyIndustries

Requirements

Deep operational experience in Patient Support Services and Oncology
Strong program development capabilities
Cross-functional leadership skills
Solutions-oriented mindset
Strategic, creative, and agile approach
Comfortable setting vision and managing day-to-day operations in a dynamic, fast-paced, growing environment
Highly motivated and experienced (implied for Director-level role)

Responsibilities

Drive the strategy, design, and execution of patient services programs in support of the commercial launch of a new oncology therapy, ensuring alignment with overall brand and access objectives
Develop comprehensive patient support services including hub services (benefits investigation, prior authorization, and appeals support), quick start/free trial programs, dose replacement programs, field reimbursement managers, Patient Assistance Program (PAP), and copay assistance program
Translate strategic goals into actionable business requirements, workflows, and performance KPIs to ensure seamless launch execution and long-term scalability of patient services
Oversee strategic vendor partnerships to build, implement, and manage patient service programs; ensure operational excellence through rigorous oversight of SOWs, SOPs, training materials, compliance standards, and patient-focused metrics
Establish a robust framework for monitoring program effectiveness, patient engagement, and satisfaction; deliver timely insights and reporting to senior leadership to inform strategic decision-making
Provide oversight of patient support services budget and forecast; manage program operational and pass-through reimbursement costs; provide regular reporting to senior leadership
Serve as a strategic partner to Access Marketing, Brand, Data & Analytics, Legal, Compliance, Medical Affairs, IT, and other cross-functional teams to ensure alignment and integration of patient services within the overall launch strategy
Lead the design, build, and implementation of an industry-leading patient support program; drive strategic development and operational excellence of Oncology patient services; manage day-to-day operations, vendor performance, and lead the Patient Services team; serve as subject matter expert on hub and patient services

Skills

Patient Support Services

Oncology

Program Management

Operations

Vendor Management

Cross-Functional Collaboration

Hub Services

Strategic Planning

Team Leadership

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free